<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089579</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102894</org_study_id>
    <nct_id>NCT04089579</nct_id>
  </id_info>
  <brief_title>hCT-MSC in Children With Autism Spectrum Disorder</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>A Phase II Study of hCT-MSC, an Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Children With Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joanne Kurtzberg, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Marcus Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase II study is to determine the efficacy of human umbilical cord&#xD;
      tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication&#xD;
      abilities in children with autism spectrum disorder (ASD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this double blinded Phase II study is to determine the efficacy of human&#xD;
      umbilical cord tissue-derived mesencymal stromal cells (hCT-MSC), administered in two&#xD;
      different dosing strategies, in children with autism spectrum disorder (ASD).&#xD;
&#xD;
      This study will be enrolling children with ASD, aging 4-11 years of age. Qualifying subjects&#xD;
      will undergo neuropsychological evaluation, EEG testing, eye tracking, CVA assessments, and&#xD;
      infusion of study product. Subjects will be randomized to one of two study arms; 1) a single&#xD;
      infusion of 6.0x106 cells/Kg at baseline, followed by a blinded placebo infusion at six&#xD;
      months or, 2) Placebo infusion at baseline, followed by an intravenous dose of 6x106 cells/Kg&#xD;
      at six months.&#xD;
&#xD;
      The primary endpoint of this study is the change in social communication skill from baseline&#xD;
      to six months. The potential risks associated with infusion of MSCs include a reaction to the&#xD;
      product (rash, shortness of breath, wheezing, difficulty breathing, hypotension, swelling&#xD;
      around the mouth, throat or eyes, tachycardia, diaphoresis), transmission of infection, and&#xD;
      HLA sensitization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study is a phase II, prospective, randomized, blinded, cross over, clinical trial designed to assess the efficacy of intravenous dosing of hCT-MSC for improving social communication abilities in young children with ASD. All participants will ultimately be treated with hCT-MSC. Participants randomized to arm A will each receive a single intravenous dose of 6x106 hCT-MSC per kilogram at baseline, followed by a placebo infusion at six months. Participants randomized to arm B will each receive a placebo infusion at baseline, followed by an intravenous dose of 6x106 hCT-MSC per kilogram at six months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded infusion</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The primary outcome measure is the mean of the change on the Socialization and Communication Subscale Standard Scores on the Vineland Adaptive Behavior Scales (VABS-3). The primary endpoint is the change on this outcome measure from baseline to six months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in VABS-3 Socialization Standard Score</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in VABS-3 (Vineland Adaptive Behavior Scales) Socialization Standard Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VABS-3 Communication Standard Score</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in VABS-3 (Vineland Adaptive Behavior Scales) Communication Standard Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-Severity score</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Clinical Global Impression- Severity Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-Intervention score</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Clinical Global Impression- Impression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Pediatric Quality of Life Scale</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Pediatric Quality of Life Scale, raw scale range of 0-2300 with higher scores indicating a higher quality of life (better outcome)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and severity of infusion reactions</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Assess for infusion reactions</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and severity of product-related infections</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Assess for infections directly related to the study product infusions</description>
  </other_outcome>
  <other_outcome>
    <measure>Evidence of formation of anti-HLA antibodies</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Assess for anti-HLA antibodies</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and severity of graft versus host disease</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Assess for signs and symptoms of graft versus host disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and severity of unexpected adverse events related to the study product</measure>
    <time_frame>Baseline, 6 months, 12 months</time_frame>
    <description>Assess for study related and unexpected adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Autism</condition>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of 6x10e6 cells/kg administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord Tissue Mesenchymal Stromal Cells</intervention_name>
    <description>Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.</description>
    <arm_group_label>MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Infusion</intervention_name>
    <description>Placebo comparative infusion</description>
    <arm_group_label>Placebo Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age ≥ 4 years to &lt; 12 years (11 years, 364 days) at the time of consent&#xD;
&#xD;
          2. Confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using the DSM-5&#xD;
             Checklist as informed by the Brief Observation of Symptoms of Autism (BOSA) and the&#xD;
             Autism Diagnostic Interview-Revised (ADI-R)&#xD;
&#xD;
          3. Fragile X testing performed and negative; CMA and/or whole exome sequencing performed&#xD;
             and results not linked to autism diagnosis&#xD;
&#xD;
          4. Stable on current psychiatric medication regimen (dose and dosing schedule) for at&#xD;
             least 2 months prior to infusion of study product&#xD;
&#xD;
          5. Normal absolute lymphocyte count (≥1200/uL for African American participants and&#xD;
             ≥1500/uL for all other participants)&#xD;
&#xD;
          6. GAI ≥ 65 via cognitive testing by study personnel&#xD;
&#xD;
          7. Participant and parent/guardian are English speaking&#xD;
&#xD;
          8. Able to travel to Duke University two times (baseline, six months), and&#xD;
             parent/guardian is able to participate in interim surveys and interviews&#xD;
&#xD;
          9. Parental/guardian consent from at least one parent/guardian&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. General:&#xD;
&#xD;
               1. Review of medical records and/or screening assessments indicates ASD diagnosis&#xD;
                  and/or GAI &gt; 65 not confident&#xD;
&#xD;
               2. Known diagnosis of any of the following coexisting psychiatric conditions:&#xD;
                  depression, bipolar disorder, schizophrenia, obsessive compulsive disorder&#xD;
                  associated with bipolar disorder, Tourette syndrome&#xD;
&#xD;
               3. Screening data suggests that participant would not be able to comply with the&#xD;
                  requirements of the study procedures as assessed by the study team&#xD;
&#xD;
               4. Family is unwilling or unable to commit to participation in all study-related&#xD;
                  assessments, including protocol follow up&#xD;
&#xD;
               5. Sibling is enrolled in this (Duke IMPACT) study&#xD;
&#xD;
          2. Genetic:&#xD;
&#xD;
               1. Records indicate that child has a known genetic syndrome such as (but not limited&#xD;
                  to) Fragile X syndrome, neurofibromatosis, Rett syndrome, tuberous sclerosis,&#xD;
                  PTEN mutation, cystic fibrosis, muscular dystrophy or a genetic defect&#xD;
                  definitively known to be associated with ASD&#xD;
&#xD;
               2. Known pathogenic mutation or copy number variation (CNV) associated with ASD&#xD;
                  (e.g., 16p11.2, 15q13.2, 2q13.3)&#xD;
&#xD;
          3. Infectious:&#xD;
&#xD;
               1. Known active CNS infection&#xD;
&#xD;
               2. Evidence of uncontrolled infection based on records or clinical assessment&#xD;
&#xD;
               3. Known HIV positivity&#xD;
&#xD;
               4. Exposure to COVID-19 in the preceding 14 days or positive COVID-19 test in the&#xD;
                  previous 28 days. Subjects with a past history of infection with COVID-19 must be&#xD;
                  symptom-free for 14 days prior to the initial visit.&#xD;
&#xD;
          4. Medical:&#xD;
&#xD;
               1. Known metabolic disorder&#xD;
&#xD;
               2. Known mitochondrial dysfunction&#xD;
&#xD;
               3. History of unstable epilepsy or uncontrolled seizure disorder, infantile spasms,&#xD;
                  Lennox Gastaut syndrome, Dravet syndrome, or other similar chronic seizure&#xD;
                  disorder&#xD;
&#xD;
               4. Active malignancy or prior malignancy that was treated with chemotherapy&#xD;
&#xD;
               5. History of a primary immunodeficiency disorder&#xD;
&#xD;
               6. History of autoimmune cytopenias (i.e., ITP, AIHA)&#xD;
&#xD;
               7. Coexisting medical condition that would place the child at increased risk for&#xD;
                  complications of study procedures&#xD;
&#xD;
               8. Concurrent genetic or acquired disease or comorbidity(ies) that could require a&#xD;
                  future stem cell transplant&#xD;
&#xD;
               9. Significant sensory (e.g., blindness, deafness, uncorrected hearing impairment)&#xD;
                  or motor (e.g., cerebral palsy) impairment&#xD;
&#xD;
              10. Impaired renal or liver function as determined by serum creatinine &gt;1.5mg/dL or&#xD;
                  total bilirubin &gt;1.3mg/dL, except in patients with known Gilbert's disease&#xD;
&#xD;
              11. Significant hematologic abnormalities defined as: Hemoglobin &lt;10.0 g/dL,&#xD;
                  Platelets &lt;150 x 10e9/uL, WBC &lt;3,000 cells/mL, ALC &lt;1200/uL for African Americans&#xD;
                  or &lt;1500/uL for all other participants.&#xD;
&#xD;
              12. Evidence of clinically relevant physical dysmorphology indicative of a genetic&#xD;
                  syndrome as assessed by the PIs or other investigators, including a medical&#xD;
                  geneticist and psychiatrists trained in identifying dysmorphic features&#xD;
                  associated with neurodevelopmental conditions.&#xD;
&#xD;
          5. Current/Prior Therapy:&#xD;
&#xD;
             a. Availability of a banked, qualified autologous cord blood unit or parents deferred&#xD;
             use of qualified, autologous cord blood unit b. History of prior cell therapy c.&#xD;
             Current or prior use of IVIG or other anti-inflammatory medications with the exception&#xD;
             of NSAIDs d. Current or prior immunosuppressive therapy i. No systemic steroid therapy&#xD;
             that has lasted &gt;2 weeks, and no systemic steroids within 3 months prior to&#xD;
             enrollment. Topical and inhaled steroids are permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Kurtzberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geraldine Dawson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia Burgess</last_name>
    <phone>919-668-3753</phone>
    <email>cordbloodtherapyinfo@dm.duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerry Hoyle</last_name>
    <phone>9196681102</phone>
    <email>cordbloodtherapyinfo@dm.duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Sun, MD</last_name>
      <email>cordbloodtherapyinfo@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Joanne Kurtzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geraldine Dawson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Sun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Joanne Kurtzberg, MD</investigator_full_name>
    <investigator_title>Professor of pediatrics</investigator_title>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Stem cell</keyword>
  <keyword>Mesenchymal Stromal Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

